Dual targeting of vascular endothelial growth factor and bone morphogenetic protein‐9/10 impairs tumor growth through inhibition of angiogenesis

Clinical development of anti‐angiogenic agents has been a major landmark in cancer therapy for several types of cancers. Signals mediated by both vascular endothelial growth factor (VEGF) and bone morphogenetic protein (BMP)‐9 and 10 have been implicated in tumor angiogenesis. However, previous stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Akatsu, Yuichi, Yoshimatsu, Yasuhiro, Tomizawa, Taishi, Takahashi, Kazuki, Katsura, Akihiro, Miyazono, Kohei, Watabe, Tetsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5276835/
https://www.ncbi.nlm.nih.gov/pubmed/28133920
http://dx.doi.org/10.1111/cas.13103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5276835/
https://www.ncbi.nlm.nih.gov/pubmed/28133920
http://dx.doi.org/10.1111/cas.13103

Ejemplares similares